SLC2A8 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21500123	1.00	1/20
SCHEMBL20339753	0.87	1/20
SCHEMBL20339799	0.86	1/20
SCHEMBL20339353	0.84	1/20
SCHEMBL20339757	0.84	1/20
SCHEMBL20338615	0.81	1/20
SCHEMBL20339979	0.81	1/20
SCHEMBL20340003	0.77	1/20
SCHEMBL20339305	0.72	1/20
SCHEMBL20339783	0.69	1/20
SCHEMBL21500126	0.68	1/20
SCHEMBL20339603	0.65	1/20
SCHEMBL20339590	0.65	1/20
SCHEMBL20339792	0.65	1/20
SCHEMBL20339257	0.64	1/20
SCHEMBL20339598	0.63	1/20
SCHEMBL20339981	0.63	1/20
SCHEMBL20339752	0.62	1/20
SCHEMBL23269336	0.62	1/20
SCHEMBL20339794	0.59	1/20

Clinical trials — most relevant to SLC2A8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration	PHASE4	COMPLETED
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.	PHASE4	COMPLETED
Effect of Anti-diabetic Drugs on Glycemic Variability	PHASE4	COMPLETED
Dapagliflozin Effect on Erythropoiesis and Physical Fitness	PHASE4	WITHDRAWN
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients	PHASE4	COMPLETED
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes	PHASE4	COMPLETED
Reformulated F75 Milk to Treat Severe Acute Malnutrition	PHASE2/PHASE3	COMPLETED
Empagliflozin in Hypertrophic Cardiomyopathy	PHASE3	ACTIVE_NOT_RECRUITING
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin	PHASE2	NOT_YET_RECRUITING
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes	PHASE2	COMPLETED
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes	PHASE2	RECRUITING
PK and PD of YG1699 in CKD Patients With Diabetes	PHASE1	NOT_YET_RECRUITING
Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans	PHASE1	COMPLETED
Multi-Tracer PET Assessment of Primary Brain Tumors	PHASE1	COMPLETED
Sodium Lactate Infusion in GLUT1DS Patients	EARLY_PHASE1	COMPLETED
A Proof-of-concept Study Evaluating the Microbiota-gut-brain Axis	nan	RECRUITING
Characterization of Abdomino-pelvic Lesions by 18Fluorine- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography	nan	NOT_YET_RECRUITING
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients	nan	COMPLETED
Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome	nan	SUSPENDED
Clinical Utility of Breath Tests in GI	nan	COMPLETED
SLC2A1 Variants and Diabetic Nephropathy	nan	COMPLETED
Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus	nan	COMPLETED
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer	nan	UNKNOWN
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.	nan	RECRUITING
Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure	nan	COMPLETED
Insulin Detemir in Obesity Management	nan	ACTIVE_NOT_RECRUITING
The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer	nan	COMPLETED
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction	nan	COMPLETED
The Effect of Green Coffee Extract on Blood Glucose Homeostasis in Healthy Adults	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC2A8 binder may also engage these)

Protein	Name	Similarity
Q9JIF3	—	1.000	Q9JIF3 →
P58354	—	0.999	P58354 →
Q9JJZ1	—	0.997	Q9JJZ1 →
Q9UGQ3	—	0.981	Q9UGQ3 →
Q91WU2	—	0.971	Q91WU2 →
Q3UDF0	—	0.970	Q3UDF0 →
B2GV36	—	0.967	B2GV36 →
P19357	—	0.966	P19357 →
Q27994	—	0.966	Q27994 →
Q9Y226	—	0.963	Q9Y226 →
P14142	—	0.963	P14142 →
Q6A4L0	—	0.963	Q6A4L0 →
Q80UJ1	—	0.962	Q80UJ1 →
Q5R540	—	0.962	Q5R540 →
Q3UHK1	—	0.961	Q3UHK1 →
SLC2A4	Solute carrier family 2, facilitated glucose transporter member 4	0.960	landscape →
Q90592	—	0.960	Q90592 →
Q9Y694	—	0.960	Q9Y694 →
A6QLW8	—	0.960	A6QLW8 →
A6NK97	—	0.958	A6NK97 →
Q5RLM2	—	0.958	Q5RLM2 →
Q9XT10	—	0.958	Q9XT10 →
Q6NUB3	—	0.957	Q6NUB3 →
Q3YAW7	—	0.957	Q3YAW7 →
P12336	—	0.957	P12336 →
Q6DFR1	—	0.956	Q6DFR1 →
Q1RPP5	—	0.955	Q1RPP5 →
O88446	—	0.955	O88446 →
Q921A2	—	0.954	Q921A2 →
Q70BM6	—	0.954	Q70BM6 →